A new personalized cancer treatment can radically improve the outlook for some patients with bile duct cancer, finds an international multicenter trial involving researchers. The clinical trial found that patients who were otherwise facing end of life care survived for up to two years when treated with the drug futibatinib. In September last year, data from the FOENIX-CCA2 trial led to the FDA to approve futibatinib. Futibatinib targets a particular genetic alteration, called FGFR2 fusion, which is found in around 14% of bile duct cancers. Of those diagnosed annually in the UK with bile duct cancer, which comprises cholangiocarcinoma and...